Home

Discover

Botswana

Biotech companies in Botswana

Search our database and find Biotech companies in Botswana based on your preferred criteria. Get key company details, track changes, and gain actionable insights to drive business growth or investment decisions.

  • 11 Botswana Biotech companies
  • 500+ data points
  • Fully updated monthly
Company Datapoints

What kind of data can you get about Biotech companies in Botswana?

Get to know our data at a glance with this sample company profile. We cover everything you need to know about Botswana Biotech companies.

Available data points

Metadata

company_id

9238086

source_id

793445

unique_domain

1

unique_website

1

last_updated_at

2025-04-04

created_at

2016-06-25

description

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.

type

Public Company

industry_group_1

Biotech

Firmographics

company_name

Affimed

company_legal_name

Affimed GmbH

industry

Biotechnology Research

founded_year

2000

size_range

51-200 employees

employees_count

88

Locations

hq_country

Botswana

hq_country_iso2

BW

hq_country_iso3

BWA

hq_location

Mannheim, BW, Botswana

hq_full_address

*******

Follower counts & changes

followers_count_professional_network

6827

followers_count_owler

97

Financials

is_public

1

ipo_date

2014-09-12

ipo_share_price

7

ipo_share_price_currency

USD

Funding

last_funding_round_name

Post-IPO Equity - Affimed

last_funding_round_announced_date

2022-04-13

last_funding_round_amount_raised

90000000

last_funding_round_amount_raised_currency

$

Technographics

num_technologies_used

5

Company websites and social media

website

https://www.affimed.com

professional_network_url

https://www.professional-network.com/company/affimed-ag

financial_website_url

https://www.financial-website.com/organization/affimed-therapeutics

JSON data sample

Copy
{
  "company_id": 9238086,
  "source_id": "793445",
  "company_name": "Affimed",
  "company_name_alias": [
    "affimed",
    "affimed n.v.",
    "affimed gmbh"
  ],
  "company_legal_name": "Affimed GmbH",
  "company_logo": "/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsK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\r\noooAKKKKACiiigAooooAKKKKACiiigD/2Q==",
  "website": "https://www.affimed.com",
  "professional_network_url": "https://www.professional-network.com/company/affimed-ag",
  "twitter_url": [
    "https://www.twitter.com/affimed?lang=en",
    "https://www.twitter.com/affimed"
  ],
  "discord_url": [],
  "facebook_url": [],
  "instagram_url": [],
  "pinterest_url": [],
  "tiktok_url": [],
  "youtube_url": [],
  "github_url": [],
  "reddit_url": [],
  "financial_website_url": "https://www.financial-website.com/organization/affimed-therapeutics",
  "stock_ticker": [
    {
      "exchange": null,
      "ticker": "AFMD"
    },
    {
      "exchange": "NASDAQ",
      "ticker": "AFMD"
    }
  ],
  "is_b2b": 0,
  "industry": "Biotechnology Research",
  "sic_codes": [
    "28",
    "283"
  ],
  "naics_codes": [
    "32",
    "325"
  ],
  "categories_and_keywords": [
    "healthcare",
    "tumor destruction",
    "cancer treatment",
    "revolutionary outcomes",
    "innate immunity",
    "tumors",
    "health",
    "clinics",
    "pharma",
    "biotechnology",
    "clinical trials",
    "health care",
    "medical",
    "therapeutics"
  ],
  "description": "Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies, which target innate immune cells, e.g. natural killer (NK) cells and macrophages, to destroy tumor cells. Affimed’s ICE® enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors with activity demonstrated as monotherapy and when given in combination with NK cells and other I-O therapeutics. Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated, relapsed / refractory (r/r) Hodkin lymphoma (HL) patients with a manageable safety profile in a clinical trial (AFM13-104). Affimed’s phase 2 study, LuminICE-203, is underway to investigate acimtamig in combination with AlloNK® (also known as AB-101), an off-the-shelf, allogeneic NK cell from Artiva Biotherapeutics, in patients with r/r HL with an exploratory arm planned in patients with r/r/ peripheral T-cell lymphoma (PTCL). AFM24 is in development for epidermal growth factor receptor (EGFR)-expressing solid tumors. Based on the data generated to date, the developmental focus of AFM24 is in combination with the anti-PD-L1 inhibitor atezolizumab in advanced stage EGFR-positive non-small cell lung cancer (NSCLC). AFM28 is being developed for patients with CD123-expressing acute myeloid leukemia (AML) in need of new therapeutic options. A first-in-human Phase 1 clinical study is underway (AFM28-101) and development in combination with allogeneic NK cell therapy is being explored.",
  "description_enriched": "Affimed is a company pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.",
  "description_metadata_raw": "Affimed (AFMD) is pioneering a transformative innate immunity therapeutic approach to eradicating solid and hematologic tumors to help patients fight cancer.",
  "type": "Public Company",
  "status": {
    "value": "active",
    "comment": "Independent Company"
  },
  "founded_year": "2000",
  "size_range": "51-200 employees",
  "employees_count": 88,
  "followers_count_professional_network": 6827,
  "followers_count_twitter": null,
  "followers_count_owler": 97,
  "hq_region": [
    "Africa",
    "Sub-Saharan Africa",
    "Southern Africa",
    "EMEA"
  ],
  "hq_country": "Botswana",
  "hq_country_iso2": "BW",
  "hq_country_iso3": "BWA",
  "hq_location": "Mannheim, BW, Botswana",
  "hq_full_address": "*******",
  "hq_city": null,
  "hq_state": null,
  "hq_street": null,
  "hq_zipcode": null,
  "company_locations_full": [
    {
      "location_address": "*******",
      "is_primary": 1
    },
    {
      "location_address": "*******",
      "is_primary": 0
    },
    {
      "location_address": "*******",
      "is_primary": 0
    },
    {
      "location_address": "*******",
      "is_primary": 0
    },
    {
      "location_address": "*******",
      "is_primary": 0
    }
  ],
  "is_public": 1,
  "ipo_date": "2014-09-12",
  "ipo_share_price": 7,
  "ipo_share_price_currency": "USD",
  "revenue_annual_range": null,
  "revenue_annual": {
    "source_5_annual_revenue": {
      "annual_revenue": 12894138,
      "annual_revenue_currency": "$"
    },
    "source_1_annual_revenue": {
      "annual_revenue": 8275000,
      "annual_revenue_currency": "€"
    }
  },
  "revenue_quarterly": {
    "value": 155000,
    "currency": "€"
  },
  "income_statements": [
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -7913000,
      "ebitda": -7814000,
      "ebitda_margin": -14.68796992481203,
      "ebit_margin": -14.87406015037594,
      "earnings_per_share": null,
      "gross_profit": 532000,
      "gross_profit_margin": 1,
      "income_tax_expense": 1000,
      "interest_expense": 243000,
      "interest_income": 29000,
      "net_income": -8203000,
      "period_display_end_date": "Q1, 2018",
      "period_end_date": "2018-03-31",
      "period_type": "q1",
      "pre_tax_profit": -8202000,
      "revenue": 532000,
      "total_operating_expense": 8346000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -9114000,
      "ebitda": -9213000,
      "ebitda_margin": -61.42,
      "ebit_margin": -60.76,
      "earnings_per_share": null,
      "gross_profit": 188000,
      "gross_profit_margin": 1.2533333333333334,
      "income_tax_expense": 0,
      "interest_expense": -243000,
      "interest_income": 782000,
      "net_income": -8014000,
      "period_display_end_date": "Q2, 2018",
      "period_end_date": "2018-06-30",
      "period_type": "q2",
      "pre_tax_profit": -8014000,
      "revenue": 150000,
      "total_operating_expense": 9401000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -12129000,
      "ebitda": -12129000,
      "ebitda_margin": -39.63725490196079,
      "ebit_margin": -39.63725490196079,
      "earnings_per_share": null,
      "gross_profit": 268000,
      "gross_profit_margin": 0.8758169934640523,
      "income_tax_expense": 0,
      "interest_expense": 669000,
      "interest_income": -687000,
      "net_income": -12020000,
      "period_display_end_date": "Q3, 2018",
      "period_end_date": "2018-09-30",
      "period_type": "q3",
      "pre_tax_profit": -12020000,
      "revenue": 306000,
      "total_operating_expense": 12397000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -19536000,
      "ebitda": -19185000,
      "ebitda_margin": -0.8082999789340636,
      "ebit_margin": -0.8230882662734359,
      "earnings_per_share": null,
      "gross_profit": 25250000,
      "gross_profit_margin": 1.0638297872340425,
      "income_tax_expense": 1000,
      "interest_expense": 847000,
      "interest_income": 256000,
      "net_income": -19477000,
      "period_display_end_date": "FY, 2018",
      "period_end_date": "2018-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -19476000,
      "revenue": 23735000,
      "total_operating_expense": 44435000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": 1018000,
      "ebitda": 1228000,
      "ebitda_margin": 0.10816524266713644,
      "ebit_margin": 0.08966792918171408,
      "earnings_per_share": null,
      "gross_profit": 11439000,
      "gross_profit_margin": 1.0075750902845062,
      "income_tax_expense": 0,
      "interest_expense": 161000,
      "interest_income": 995000,
      "net_income": 1852000,
      "period_display_end_date": "Q1, 2019",
      "period_end_date": "2019-03-31",
      "period_type": "q1",
      "pre_tax_profit": 1852000,
      "revenue": 11353000,
      "total_operating_expense": 10211000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -9682000,
      "ebitda": -9892000,
      "ebitda_margin": -2.468063872255489,
      "ebit_margin": -2.415668662674651,
      "earnings_per_share": null,
      "gross_profit": 4205000,
      "gross_profit_margin": 1.0491516966067864,
      "income_tax_expense": 4000,
      "interest_expense": 122000,
      "interest_income": -560000,
      "net_income": -10340000,
      "period_display_end_date": "Q2, 2019",
      "period_end_date": "2019-06-30",
      "period_type": "q2",
      "pre_tax_profit": -10336000,
      "revenue": 4008000,
      "total_operating_expense": 14097000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -12691000,
      "ebitda": -12691000,
      "ebitda_margin": -6.03471231573942,
      "ebit_margin": -6.03471231573942,
      "earnings_per_share": null,
      "gross_profit": 1820000,
      "gross_profit_margin": 0.8654303376129339,
      "income_tax_expense": 0,
      "interest_expense": 106000,
      "interest_income": 488000,
      "net_income": -10884000,
      "period_display_end_date": "Q3, 2019",
      "period_end_date": "2019-09-30",
      "period_type": "q3",
      "pre_tax_profit": -10884000,
      "revenue": 2103000,
      "total_operating_expense": 14511000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -32376000,
      "ebitda": -31651000,
      "ebitda_margin": -1.4796409705016127,
      "ebit_margin": -1.5135337291384228,
      "earnings_per_share": null,
      "gross_profit": 21681000,
      "gross_profit_margin": 1.013557103454724,
      "income_tax_expense": 4000,
      "interest_expense": 483000,
      "interest_income": 602000,
      "net_income": -32365000,
      "period_display_end_date": "FY, 2019",
      "period_end_date": "2019-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -32361000,
      "revenue": 21391000,
      "total_operating_expense": 53332000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -9896000,
      "ebitda": -9896000,
      "ebitda_margin": -1.9271665043816943,
      "ebit_margin": -1.9271665043816943,
      "earnings_per_share": null,
      "gross_profit": 5135000,
      "gross_profit_margin": 1,
      "income_tax_expense": 0,
      "interest_expense": 64000,
      "interest_income": 0,
      "net_income": -8289000,
      "period_display_end_date": "Q1, 2020",
      "period_end_date": "2020-03-31",
      "period_type": "q1",
      "pre_tax_profit": -8289000,
      "revenue": 5135000,
      "total_operating_expense": 15031000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -11284000,
      "ebitda": -11284000,
      "ebitda_margin": -3.8459441036128155,
      "ebit_margin": -3.8459441036128155,
      "earnings_per_share": null,
      "gross_profit": 2962000,
      "gross_profit_margin": 1.009543285616905,
      "income_tax_expense": 0,
      "interest_expense": 65000,
      "interest_income": 0,
      "net_income": -12238000,
      "period_display_end_date": "Q2, 2020",
      "period_end_date": "2020-06-30",
      "period_type": "q2",
      "pre_tax_profit": -12238000,
      "revenue": 2934000,
      "total_operating_expense": 14246000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -2909000,
      "ebitda": -2909000,
      "ebitda_margin": -0.27586533902323374,
      "ebit_margin": -0.27586533902323374,
      "earnings_per_share": null,
      "gross_profit": 10647000,
      "gross_profit_margin": 1.0096728307254623,
      "income_tax_expense": 0,
      "interest_expense": 45000,
      "interest_income": 0,
      "net_income": -5966000,
      "period_display_end_date": "Q3, 2020",
      "period_end_date": "2020-09-30",
      "period_type": "q3",
      "pre_tax_profit": -5966000,
      "revenue": 10545000,
      "total_operating_expense": 13556000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -34718000,
      "ebitda": -33884000,
      "ebitda_margin": -1.1947813822284907,
      "ebit_margin": -1.2241889985895629,
      "earnings_per_share": null,
      "gross_profit": 28986000,
      "gross_profit_margin": 1.0220733427362483,
      "income_tax_expense": 1000,
      "interest_expense": 140000,
      "interest_income": 186000,
      "net_income": -41366000,
      "period_display_end_date": "FY, 2020",
      "period_end_date": "2020-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -41365000,
      "revenue": 28360000,
      "total_operating_expense": 62870000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -4085000,
      "ebitda": -4085000,
      "ebitda_margin": -0.3503731023243846,
      "ebit_margin": -0.3503731023243846,
      "earnings_per_share": null,
      "gross_profit": 11806000,
      "gross_profit_margin": 1.0126082854447207,
      "income_tax_expense": 2000,
      "interest_expense": 123000,
      "interest_income": 0,
      "net_income": 1412000,
      "period_display_end_date": "Q1, 2021",
      "period_end_date": "2021-03-31",
      "period_type": "q1",
      "pre_tax_profit": 1414000,
      "revenue": 11659000,
      "total_operating_expense": 15891000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -17200000,
      "ebitda": -16576000,
      "ebitda_margin": -1.7076336664262903,
      "ebit_margin": -1.771917173173998,
      "earnings_per_share": null,
      "gross_profit": 10039000,
      "gross_profit_margin": 1.0342021221798703,
      "income_tax_expense": 0,
      "interest_expense": 343000,
      "interest_income": 0,
      "net_income": -18752000,
      "period_display_end_date": "Q2, 2021",
      "period_end_date": "2021-06-30",
      "period_type": "q2",
      "pre_tax_profit": -18752000,
      "revenue": 9707000,
      "total_operating_expense": 26615000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -18569000,
      "ebitda": -19193000,
      "ebitda_margin": -2.2157700300161625,
      "ebit_margin": -2.1437312398984067,
      "earnings_per_share": null,
      "gross_profit": 8893000,
      "gross_profit_margin": 1.0266682059570538,
      "income_tax_expense": 0,
      "interest_expense": 335000,
      "interest_income": 0,
      "net_income": -17095000,
      "period_display_end_date": "Q3, 2021",
      "period_end_date": "2021-09-30",
      "period_type": "q3",
      "pre_tax_profit": -17095000,
      "revenue": 8662000,
      "total_operating_expense": 28086000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -64030000,
      "ebitda": -62697000,
      "ebitda_margin": -1.553213100133776,
      "ebit_margin": -1.586235941138582,
      "earnings_per_share": null,
      "gross_profit": 41676000,
      "gross_profit_margin": 1.0324530545508597,
      "income_tax_expense": 2000,
      "interest_expense": 1127000,
      "interest_income": 0,
      "net_income": -57523000,
      "period_display_end_date": "FY, 2021",
      "period_end_date": "2021-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -57521000,
      "revenue": 40366000,
      "total_operating_expense": 104373000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -17134000,
      "ebitda": -17134000,
      "ebitda_margin": -2.1401448913315013,
      "ebit_margin": -2.1401448913315013,
      "earnings_per_share": null,
      "gross_profit": 8290000,
      "gross_profit_margin": 1.0354733949537847,
      "income_tax_expense": 2000,
      "interest_expense": 444000,
      "interest_income": 0,
      "net_income": -16665000,
      "period_display_end_date": "Q1, 2022",
      "period_end_date": "2022-03-31",
      "period_type": "q1",
      "pre_tax_profit": -16663000,
      "revenue": 8006000,
      "total_operating_expense": 25424000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -21662000,
      "ebitda": -21662000,
      "ebitda_margin": -2.9669908231749074,
      "ebit_margin": -2.9669908231749074,
      "earnings_per_share": null,
      "gross_profit": 7541000,
      "gross_profit_margin": 1.0328722092863991,
      "income_tax_expense": 0,
      "interest_expense": 400000,
      "interest_income": 0,
      "net_income": -19409000,
      "period_display_end_date": "Q2, 2022",
      "period_end_date": "2022-06-30",
      "period_type": "q2",
      "pre_tax_profit": -19409000,
      "revenue": 7301000,
      "total_operating_expense": 29203000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -19209000,
      "ebitda": -19209000,
      "ebitda_margin": -1.2902337452982269,
      "ebit_margin": -1.2902337452982269,
      "earnings_per_share": null,
      "gross_profit": 15006000,
      "gross_profit_margin": 1.0079258463191831,
      "income_tax_expense": 0,
      "interest_expense": 323000,
      "interest_income": 0,
      "net_income": -16490000,
      "period_display_end_date": "Q3, 2022",
      "period_end_date": "2022-09-30",
      "period_type": "q3",
      "pre_tax_profit": -16490000,
      "revenue": 14888000,
      "total_operating_expense": 34215000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -88119000,
      "ebitda": -85219000,
      "ebitda_margin": -2.060769472589655,
      "ebit_margin": -2.130897395594032,
      "earnings_per_share": null,
      "gross_profit": 42770000,
      "gross_profit_margin": 1.0342659541024835,
      "income_tax_expense": 2000,
      "interest_expense": 1630000,
      "interest_income": 0,
      "net_income": -86004000,
      "period_display_end_date": "FY, 2022",
      "period_end_date": "2022-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -86002000,
      "revenue": 41353000,
      "total_operating_expense": 127989000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -31461000,
      "ebitda": -31461000,
      "ebitda_margin": -6.975831485587583,
      "ebit_margin": -6.975831485587583,
      "earnings_per_share": null,
      "gross_profit": 4920000,
      "gross_profit_margin": 1.0909090909090908,
      "income_tax_expense": 3000,
      "interest_expense": 477000,
      "interest_income": 0,
      "net_income": -31983000,
      "period_display_end_date": "Q1, 2023",
      "period_end_date": "2023-03-31",
      "period_type": "q1",
      "pre_tax_profit": -31980000,
      "revenue": 4510000,
      "total_operating_expense": 36381000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -29442000,
      "ebitda": -29442000,
      "ebitda_margin": -21.181294964028776,
      "ebit_margin": -21.181294964028776,
      "earnings_per_share": null,
      "gross_profit": 2107000,
      "gross_profit_margin": 1.5158273381294964,
      "income_tax_expense": 0,
      "interest_expense": 470000,
      "interest_income": 0,
      "net_income": -29395000,
      "period_display_end_date": "Q2, 2023",
      "period_end_date": "2023-06-30",
      "period_type": "q2",
      "pre_tax_profit": -29395000,
      "revenue": 1390000,
      "total_operating_expense": 31549000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -24923000,
      "ebitda": -24923000,
      "ebitda_margin": -12.702854230377167,
      "ebit_margin": -12.702854230377167,
      "earnings_per_share": null,
      "gross_profit": 1956000,
      "gross_profit_margin": 0.9969418960244648,
      "income_tax_expense": 0,
      "interest_expense": 447000,
      "interest_income": 138000,
      "net_income": -24355000,
      "period_display_end_date": "Q3, 2023",
      "period_end_date": "2023-09-30",
      "period_type": "q3",
      "pre_tax_profit": -24355000,
      "revenue": 1962000,
      "total_operating_expense": 26879000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -106661000,
      "ebitda": -104912000,
      "ebitda_margin": -12.678187311178247,
      "ebit_margin": -12.889546827794561,
      "earnings_per_share": null,
      "gross_profit": 12972000,
      "gross_profit_margin": 1.5676132930513595,
      "income_tax_expense": 3000,
      "interest_expense": 1806000,
      "interest_income": 509000,
      "net_income": -105938000,
      "period_display_end_date": "FY, 2023",
      "period_end_date": "2023-12-31",
      "period_type": "fiscal_year",
      "pre_tax_profit": -105935000,
      "revenue": 8275000,
      "total_operating_expense": 117884000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -19535000,
      "ebitda": -19535000,
      "ebitda_margin": -126.03225806451613,
      "ebit_margin": -126.03225806451613,
      "earnings_per_share": null,
      "gross_profit": 332000,
      "gross_profit_margin": 2.141935483870968,
      "income_tax_expense": 0,
      "interest_expense": 363000,
      "interest_income": 367000,
      "net_income": -19175000,
      "period_display_end_date": "Q1, 2024",
      "period_end_date": "2024-03-31",
      "period_type": "q1",
      "pre_tax_profit": -19175000,
      "revenue": 155000,
      "total_operating_expense": 19867000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -15553000,
      "ebitda": -15553000,
      "ebitda_margin": -100.99350649350649,
      "ebit_margin": -100.99350649350649,
      "earnings_per_share": null,
      "gross_profit": 210000,
      "gross_profit_margin": 1.3636363636363635,
      "income_tax_expense": 3000,
      "interest_expense": 351000,
      "interest_income": 306000,
      "net_income": -15451000,
      "period_display_end_date": "Q2, 2024",
      "period_end_date": "2024-06-30",
      "period_type": "q2",
      "pre_tax_profit": -15448000,
      "revenue": 154000,
      "total_operating_expense": 15763000
    },
    {
      "cost_of_goods_sold": 0,
      "cost_of_goods_sold_currency": "€",
      "ebit": -14283000,
      "ebitda": -11338000,
      "ebitda_margin": -73.14838709677419,
      "ebit_margin": -92.14838709677419,
      "earnings_per_share": null,
      "gross_profit": 164000,
      "gross_profit_margin": 1.0580645161290323,
      "income_tax_expense": 1000,
      "interest_expense": 325000,
      "interest_income": 228000,
      "net_income": -15139000,
      "period_display_end_date": "Q3, 2024",
      "period_end_date": "2024-09-30",
      "period_type": "q3",
      "pre_tax_profit": -15138000,
      "revenue": 155000,
      "total_operating_expense": 11502000
    }
  ],
  "stock_information": [
    {
      "closing_price": 2.140000104904175,
      "currency": "$",
      "date": "2022-11-30",
      "marketcap": 256365600
    },
    {
      "closing_price": 3.099999904632568,
      "currency": "$",
      "date": "2022-05-31",
      "marketcap": 371370688
    },
    {
      "closing_price": 0.597999989986419,
      "currency": "$",
      "date": "2023-06-30",
      "marketcap": 89334600
    },
    {
      "closing_price": 6.179999828338623,
      "currency": "$",
      "date": "2021-09-30",
      "marketcap": 735129536
    },
    {
      "closing_price": 0.550999999046325,
      "currency": "$",
      "date": "2024-01-31",
      "marketcap": 82285792
    },
    {
      "closing_price": 5.91,
      "currency": "$",
      "date": "2021-11-12",
      "marketcap": 576946645
    },
    {
      "closing_price": 2.059999942779541,
      "currency": "$",
      "date": "2022-09-30",
      "marketcap": 246781808
    },
    {
      "closing_price": 5.52,
      "currency": "$",
      "date": "2021-12-31",
      "marketcap": 559254925
    },
    {
      "closing_price": 3.359999895095825,
      "currency": "$",
      "date": "2024-09-30",
      "marketcap": 52687488
    },
    {
      "closing_price": 5.449999809265137,
      "currency": "$",
      "date": "2024-06-28",
      "marketcap": 82989872
    },
    {
      "closing_price": 0.47799998521804804,
      "currency": "$",
      "date": "2023-09-29",
      "marketcap": 71369112
    },
    {
      "closing_price": 5.07,
      "currency": "$",
      "date": "2024-07-31",
      "marketcap": 77203425
    },
    {
      "closing_price": 5.300000190734863,
      "currency": "$",
      "date": "2024-03-28",
      "marketcap": 79149672
    },
    {
      "closing_price": 3.349999904632568,
      "currency": "$",
      "date": "2024-10-29",
      "marketcap": 52530680
    },
    {
      "closing_price": 0.625,
      "currency": "$",
      "date": "2023-12-29",
      "marketcap": 93336880
    },
    {
      "closing_price": 4.35,
      "currency": "$",
      "date": "2024-05-31",
      "marketcap": 61823500
    },
    {
      "closing_price": 2.769999980926513,
      "currency": "$",
      "date": "2022-06-30",
      "marketcap": 331837696
    },
    {
      "closing_price": 0.9089999794960021,
      "currency": "$",
      "date": "2023-02-28",
      "marketcap": 135779024
    },
    {
      "closing_price": 0.8999999761581421,
      "currency": "$",
      "date": "2023-04-27",
      "marketcap": 134405104
    },
    {
      "closing_price": 5.349999904632568,
      "currency": "$",
      "date": "2024-04-30",
      "marketcap": 81467120
    },
    {
      "closing_price": 4.409999847412109,
      "currency": "$",
      "date": "2022-02-28",
      "marketcap": 528304736
    },
    {
      "closing_price": 6.800000190734863,
      "currency": "$",
      "date": "2021-10-29",
      "marketcap": 788658432
    },
    {
      "closing_price": 0.5899999737739561,
      "currency": "$",
      "date": "2023-07-31",
      "marketcap": 88110008
    },
    {
      "closing_price": 2.829999923706054,
      "currency": "$",
      "date": "2022-07-29",
      "marketcap": 339025504
    },
    {
      "closing_price": 0.395000010728836,
      "currency": "$",
      "date": "2023-10-31",
      "marketcap": 58988908
    },
    {
      "closing_price": 4.230000019073486,
      "currency": "$",
      "date": "2024-08-30",
      "marketcap": 67305224
    },
    {
      "closing_price": 4.079999923706055,
      "currency": "$",
      "date": "2022-01-31",
      "marketcap": 488771744
    },
    {
      "closing_price": 1.240000009536743,
      "currency": "$",
      "date": "2022-12-30",
      "marketcap": 148548288
    },
    {
      "closing_price": 1.759999990463256,
      "currency": "$",
      "date": "2022-10-31",
      "marketcap": 210842720
    },
    {
      "closing_price": 0.8799999952316281,
      "currency": "$",
      "date": "2023-05-31",
      "marketcap": 131373528
    },
    {
      "closing_price": 0.7459999918937681,
      "currency": "$",
      "date": "2023-03-31",
      "marketcap": 111347160
    },
    {
      "closing_price": 4.369999885559082,
      "currency": "$",
      "date": "2022-03-31",
      "marketcap": 523512864
    },
    {
      "closing_price": 7.039999961853027,
      "currency": "$",
      "date": "2021-08-31",
      "marketcap": 837429120
    },
    {
      "closing_price": 0.44999998807907104,
      "currency": "$",
      "date": "2023-11-30",
      "marketcap": 67202552
    },
    {
      "closing_price": 2.619999885559082,
      "currency": "$",
      "date": "2022-08-31",
      "marketcap": 313868128
    },
    {
      "closing_price": 0.544000029563903,
      "currency": "$",
      "date": "2023-08-31",
      "marketcap": 81240424
    },
    {
      "closing_price": 1.289999961853027,
      "currency": "$",
      "date": "2023-01-31",
      "marketcap": 154538128
    },
    {
      "closing_price": 0.601999998092651,
      "currency": "$",
      "date": "2024-02-29",
      "marketcap": 89902080
    },
    {
      "closing_price": 3.789999961853027,
      "currency": "$",
      "date": "2022-04-27",
      "marketcap": 454030624
    }
  ],
  "last_funding_round_name": "Post-IPO Equity - Affimed",
  "last_funding_round_announced_date": "2022-04-13",
  "last_funding_round_lead_investors": [],
  "last_funding_round_amount_raised": 90000000,
  "last_funding_round_amount_raised_currency": "$",
  "last_funding_round_num_investors": null,
  "funding_rounds": [
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2022-04-13",
      "lead_investors": [],
      "amount_raised": 90000000,
      "amount_raised_currency": "$",
      "num_investors": null
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2021-01-12",
      "lead_investors": [],
      "amount_raised": 115000000,
      "amount_raised_currency": "$",
      "num_investors": null
    },
    {
      "name": "Post-IPO Debt - Affimed",
      "announced_date": "2021-01-11",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 12160006,
      "amount_raised_currency": "$",
      "num_investors": 1
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2019-11-07",
      "lead_investors": [],
      "amount_raised": 34500000,
      "amount_raised_currency": "$",
      "num_investors": null
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2018-08-27",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 96000000,
      "amount_raised_currency": "$",
      "num_investors": 1
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2017-01-19",
      "lead_investors": [],
      "amount_raised": 16600000,
      "amount_raised_currency": "$",
      "num_investors": null
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2015-10-01",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 21376011,
      "amount_raised_currency": "$",
      "num_investors": 1
    },
    {
      "name": "Post-IPO Equity - Affimed",
      "announced_date": "2015-05-04",
      "lead_investors": [],
      "amount_raised": 37100000,
      "amount_raised_currency": "$",
      "num_investors": null
    },
    {
      "name": "Grant - Affimed",
      "announced_date": "2015-01-07",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 3000000,
      "amount_raised_currency": "$",
      "num_investors": 1
    },
    {
      "name": "Debt Financing - Affimed",
      "announced_date": "2014-09-02",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 14000000,
      "amount_raised_currency": "$",
      "num_investors": 1
    },
    {
      "name": "Series E - Affimed",
      "announced_date": "2014-09-02",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 15700000,
      "amount_raised_currency": "$",
      "num_investors": 5
    },
    {
      "name": "Series D - Affimed",
      "announced_date": "2012-10-08",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 20101102,
      "amount_raised_currency": "$",
      "num_investors": 5
    },
    {
      "name": "Series B - Affimed",
      "announced_date": "2007-04-04",
      "lead_investors": [
        "********",
        "********",
        "********"
      ],
      "amount_raised": 32000000,
      "amount_raised_currency": "$",
      "num_investors": 4
    },
    {
      "name": "Grant - Affimed",
      "announced_date": "2015-01-07",
      "lead_investors": [
        "********"
      ],
      "amount_raised": 3000000,
      "amount_raised_currency": "$",
      "num_investors": 1
    }
  ],
  "ownership_status": "Public",
  "parent_company_information": null,
  "acquired_by_summary": null,
  "num_acquisitions_source_1": null,
  "acquisition_list_source_1": [],
  "num_acquisitions_source_2": null,
  "acquisition_list_source_2": [],
  "num_acquisitions_source_5": null,
  "acquisition_list_source_5": [],
  "competitors": [
    {
      "company_name": "juno therapeutics",
      "similarity_score": 8999
    },
    {
      "company_name": "eolo-pharma",
      "similarity_score": 5263
    },
    {
      "company_name": "ose immunotherapeutics",
      "similarity_score": 6126
    },
    {
      "company_name": "carisma",
      "similarity_score": 7197
    },
    {
      "company_name": "array biopharma",
      "similarity_score": null
    },
    {
      "company_name": "skyepharma",
      "similarity_score": null
    },
    {
      "company_name": "neximmune",
      "similarity_score": 7008
    },
    {
      "company_name": "tcr2",
      "similarity_score": 8117
    },
    {
      "company_name": "fate therapeutics",
      "similarity_score": 5538
    },
    {
      "company_name": "btg",
      "similarity_score": null
    },
    {
      "company_name": "tricida",
      "similarity_score": null
    },
    {
      "company_name": "allogene",
      "similarity_score": 10023
    },
    {
      "company_name": "gilead",
      "similarity_score": 5187
    },
    {
      "company_name": "morphosys",
      "similarity_score": 5604
    },
    {
      "company_name": "zymeworks",
      "similarity_score": 7482
    },
    {
      "company_name": "medigene",
      "similarity_score": 94679
    },
    {
      "company_name": "aldeyra therapeutics",
      "similarity_score": 6325
    },
    {
      "company_name": "adaptimmune",
      "similarity_score": 100000
    },
    {
      "company_name": "immunocore",
      "similarity_score": 99497
    },
    {
      "company_name": "iovance",
      "similarity_score": 6059
    },
    {
      "company_name": "regeneron",
      "similarity_score": 5481
    },
    {
      "company_name": "immatics",
      "similarity_score": 11948
    },
    {
      "company_name": "noxxon pharma",
      "similarity_score": 6296
    }
  ],
  "competitors_websites": [],
  "company_phone_numbers": [
    "********",
    "********",
    "********",
    "********"
  ],
  "company_emails": [
    "****@affimed.com"
  ],
  "pricing_available": 0,
  "free_trial_available": 0,
  "demo_available": 0,
  "is_downloadable": 0,
  "mobile_apps_exist": 0,
  "online_reviews_exist": 0,
  "documentation_exist": 0,
  "product_reviews_count": null,
  "product_reviews_aggregate_score": null,
  "product_reviews_score_distribution": null,
  "product_pricing_summary": [],
  "num_news_articles": null,
  "news_articles": [],
  "num_technologies_used": 5,
  "technologies_used": [
    {
      "technology": "gmail",
      "first_verified_at": "2024-06-10",
      "last_verified_at": "2024-08-26"
    },
    {
      "technology": "well",
      "first_verified_at": "2024-05-20",
      "last_verified_at": "2025-03-31"
    },
    {
      "technology": "c",
      "first_verified_at": "2024-05-20",
      "last_verified_at": "2025-03-31"
    },
    {
      "technology": "amp",
      "first_verified_at": "2024-05-20",
      "last_verified_at": "2025-03-31"
    },
    {
      "technology": "impact",
      "first_verified_at": "2024-04-04",
      "last_verified_at": "2024-05-13"
    }
  ],
  "total_website_visits_monthly": null,
  "visits_change_monthly": null,
  "rank_global": null,
  "rank_country": null,
  "rank_category": null,
  "visits_breakdown_by_country": [],
  "visits_breakdown_by_gender": null,
  "visits_breakdown_by_age": null,
  "bounce_rate": null,
  "pages_per_visit": null,
  "average_visit_duration_seconds": null,
  "similarly_ranked_websites": [],
  "top_topics": [],
  "company_employee_reviews_count": null,
  "company_employee_reviews_aggregate_score": null,
  "employee_reviews_score_breakdown": null,
  "employee_reviews_score_distribution": null,
  "active_job_postings_count": null,
  "active_job_postings_titles": [],
  "base_salary": [],
  "additional_pay": [],
  "total_salary": [],
  "employees_count_breakdown_by_seniority": {
    "employees_count_owner": 0,
    "employees_count_founder": 0,
    "employees_count_clevel": 3,
    "employees_count_partner": 0,
    "employees_count_vp": 7,
    "employees_count_head": 2,
    "employees_count_director": 6,
    "employees_count_manager": 16,
    "employees_count_senior": 6,
    "employees_count_intern": 0,
    "employees_count_specialist": 16,
    "employees_count_other_management": 15
  },
  "employees_count_breakdown_by_department": {
    "employees_count_medical": 5,
    "employees_count_sales": 1,
    "employees_count_hr": 4,
    "employees_count_legal": 1,
    "employees_count_marketing": 2,
    "employees_count_finance": 1,
    "employees_count_technical": 4,
    "employees_count_consulting": 0,
    "employees_count_operations": 7,
    "employees_count_product": 0,
    "employees_count_general_management": 9,
    "employees_count_administrative": 0,
    "employees_count_customer_service": 0,
    "employees_count_project_management": 5,
    "employees_count_design": 0,
    "employees_count_research": 14,
    "employees_count_trades": 0,
    "employees_count_real_estate": 0,
    "employees_count_education": 0,
    "employees_count_other_department": 18
  },
  "employees_count_breakdown_by_region": {
    "employees_count_eastern_europe": 0,
    "employees_count_latin_america": 0,
    "employees_count_southern_europe": 1,
    "employees_count_sub_saharan_africa": 0,
    "employees_count_central_asia": 0,
    "employees_count_northern_america": 8,
    "employees_count_australia_new_zealand": 0,
    "employees_count_northern_europe": 1,
    "employees_count_south_eastern_asia": 0,
    "employees_count_polynesia": 0,
    "employees_count_southern_asia": 0,
    "employees_count_northern_africa": 0,
    "employees_count_melanesia": 0,
    "employees_count_western_europe": 61,
    "employees_count_western_asia": 0,
    "employees_count_eastern_asia": 0,
    "employees_count_micronesia": 0,
    "employees_count_unknown": 0
  },
  "employees_count_by_country": [
    {
      "country": "United Kingdom",
      "employee_count": 1
    },
    {
      "country": "Switzerland",
      "employee_count": 2
    },
    {
      "country": "United States",
      "employee_count": 8
    },
    {
      "country": "France",
      "employee_count": 2
    },
    {
      "country": "Austria",
      "employee_count": 2
    },
    {
      "country": "Germany",
      "employee_count": 54
    },
    {
      "country": "Netherlands",
      "employee_count": 1
    },
    {
      "country": "Spain",
      "employee_count": 1
    }
  ],
  "key_executives": [
    {
      "member_id": 82197925,
      "member_full_name": "*******",
      "member_position_title": "Director Procurement"
    },
    {
      "member_id": 224285965,
      "member_full_name": "*******",
      "member_position_title": "CFO"
    },
    {
      "member_id": 284281141,
      "member_full_name": "*******",
      "member_position_title": "Head Of Drug Supply"
    },
    {
      "member_id": 420952559,
      "member_full_name": "*******",
      "member_position_title": "Medical Director"
    },
    {
      "member_id": 394821732,
      "member_full_name": "*******",
      "member_position_title": "Director Commercial Development"
    },
    {
      "member_id": 65744794,
      "member_full_name": "*******",
      "member_position_title": "Head Of Information Security"
    },
    {
      "member_id": 395148020,
      "member_full_name": "*******",
      "member_position_title": "Head Of Marketing And Communications"
    },
    {
      "member_id": 247160550,
      "member_full_name": "*******",
      "member_position_title": "General Counsel"
    },
    {
      "member_id": 413800944,
      "member_full_name": "*******",
      "member_position_title": "Research Associate Translational Immunobiology"
    },
    {
      "member_id": 340385628,
      "member_full_name": "*******",
      "member_position_title": "Principal Statistician And Head Of Programming"
    },
    {
      "member_id": 341701203,
      "member_full_name": "*******",
      "member_position_title": "Chief Medical Officer And Member Of Executive Management Board"
    },
    {
      "member_id": 424912848,
      "member_full_name": "*******",
      "member_position_title": "Quality GMP Manager"
    },
    {
      "member_id": 613003726,
      "member_full_name": "*******",
      "member_position_title": "Medical Director Research And Development"
    },
    {
      "member_id": 431224317,
      "member_full_name": "*******",
      "member_position_title": "Chief Operating And Strategy Officer"
    },
    {
      "member_id": 540355869,
      "member_full_name": "*******",
      "member_position_title": "Vorstand"
    }
  ],
  "key_employee_change_events": [
    {
      "employee_change_event_name": "*******",
      "employee_change_event_date": "2024-09-03",
      "employee_change_event_url": null
    }
  ],
  "key_executive_arrivals": [],
  "key_executive_departures": [
    {
      "member_id": 431224317,
      "member_full_name": "*******",
      "member_position_title": "Chief Operating Officer",
      "departure_date": "Nov 2024"
    }
  ],
  "employees_count_change": {
    "current": 90,
    "change_monthly": -1,
    "change_monthly_percentage": -1.098901098901099,
    "change_quarterly": -9,
    "change_quarterly_percentage": -9.090909090909092,
    "change_yearly": -55,
    "change_yearly_percentage": -37.93103448275862
  },
  "employees_count_by_month": [
    {
      "employees_count": 62,
      "date": "2019-11"
    },
    {
      "employees_count": 145,
      "date": "2024-04"
    },
    {
      "employees_count": 154,
      "date": "2023-04"
    },
    {
      "employees_count": 112,
      "date": "2021-12"
    },
    {
      "employees_count": 148,
      "date": "2023-01"
    },
    {
      "employees_count": 148,
      "date": "2022-12"
    },
    {
      "employees_count": 106,
      "date": "2021-10"
    },
    {
      "employees_count": 109,
      "date": "2021-11"
    },
    {
      "employees_count": 149,
      "date": "2023-02"
    },
    {
      "employees_count": 127,
      "date": "2024-05"
    },
    {
      "employees_count": 134,
      "date": "2022-09"
    },
    {
      "employees_count": 80,
      "date": "2020-10"
    },
    {
      "employees_count": 47,
      "date": "2019-05"
    },
    {
      "employees_count": 44,
      "date": "2019-01"
    },
    {
      "employees_count": 138,
      "date": "2022-10"
    },
    {
      "employees_count": 101,
      "date": "2024-12"
    },
    {
      "employees_count": 72,
      "date": "2020-08"
    },
    {
      "employees_count": 153,
      "date": "2023-06"
    },
    {
      "employees_count": 85,
      "date": "2021-03"
    },
    {
      "employees_count": 127,
      "date": "2022-06"
    },
    {
      "employees_count": 115,
      "date": "2022-02"
    },
    {
      "employees_count": 143,
      "date": "2023-11"
    },
    {
      "employees_count": 115,
      "date": "2022-01"
    },
    {
      "employees_count": 105,
      "date": "2024-09"
    },
    {
      "employees_count": 112,
      "date": "2024-07"
    },
    {
      "employees_count": 106,
      "date": "2024-10"
    },
    {
      "employees_count": 63,
      "date": "2019-12"
    },
    {
      "employees_count": 154,
      "date": "2023-09"
    },
    {
      "employees_count": 152,
      "date": "2023-03"
    },
    {
      "employees_count": 139,
      "date": "2024-02"
    },
    {
      "employees_count": 66,
      "date": "2020-03"
    },
    {
      "employees_count": 141,
      "date": "2022-11"
    },
    {
      "employees_count": 98,
      "date": "2025-02"
    },
    {
      "employees_count": 120,
      "date": "2022-04"
    },
    {
      "employees_count": 119,
      "date": "2024-06"
    },
    {
      "employees_count": 78,
      "date": "2020-12"
    },
    {
      "employees_count": 92,
      "date": "2021-06"
    },
    {
      "employees_count": 117,
      "date": "2022-03"
    },
    {
      "employees_count": 47,
      "date": "2019-03"
    },
    {
      "employees_count": 80,
      "date": "2020-11"
    },
    {
      "employees_count": 99,
      "date": "2025-01"
    },
    {
      "employees_count": 145,
      "date": "2024-03"
    },
    {
      "employees_count": 82,
      "date": "2021-02"
    },
    {
      "employees_count": 91,
      "date": "2025-03"
    },
    {
      "employees_count": 139,
      "date": "2023-12"
    },
    {
      "employees_count": 110,
      "date": "2024-08"
    },
    {
      "employees_count": 78,
      "date": "2020-09"
    },
    {
      "employees_count": 57,
      "date": "2019-10"
    },
    {
      "employees_count": 102,
      "date": "2021-09"
    },
    {
      "employees_count": 47,
      "date": "2019-04"
    },
    {
      "employees_count": 67,
      "date": "2020-07"
    },
    {
      "employees_count": 131,
      "date": "2022-07"
    },
    {
      "employees_count": 57,
      "date": "2019-09"
    },
    {
      "employees_count": 154,
      "date": "2023-05"
    },
    {
      "employees_count": 69,
      "date": "2020-05"
    },
    {
      "employees_count": 60,
      "date": "2020-02"
    },
    {
      "employees_count": 66,
      "date": "2020-06"
    },
    {
      "employees_count": 88,
      "date": "2021-04"
    },
    {
      "employees_count": 90,
      "date": "2021-05"
    },
    {
      "employees_count": 53,
      "date": "2019-06"
    },
    {
      "employees_count": 141,
      "date": "2024-01"
    },
    {
      "employees_count": 62,
      "date": "2020-01"
    },
    {
      "employees_count": 155,
      "date": "2023-08"
    },
    {
      "employees_count": 104,
      "date": "2024-11"
    },
    {
      "employees_count": 159,
      "date": "2023-07"
    },
    {
      "employees_count": 53,
      "date": "2019-07"
    },
    {
      "employees_count": 90,
      "date": "2025-04"
    },
    {
      "employees_count": 130,
      "date": "2022-08"
    },
    {
      "employees_count": 65,
      "date": "2020-04"
    },
    {
      "employees_count": 97,
      "date": "2021-07"
    },
    {
      "employees_count": 148,
      "date": "2023-10"
    },
    {
      "employees_count": 44,
      "date": "2019-02"
    },
    {
      "employees_count": 122,
      "date": "2022-05"
    },
    {
      "employees_count": 79,
      "date": "2021-01"
    },
    {
      "employees_count": 57,
      "date": "2019-08"
    },
    {
      "employees_count": 99,
      "date": "2021-08"
    }
  ],
  "professional_network_followers_count_change": {
    "current": 6779,
    "change_monthly": 11,
    "change_monthly_percentage": 0.16252955082742315,
    "change_quarterly": 182,
    "change_quarterly_percentage": 2.758829771108079,
    "change_yearly": 911,
    "change_yearly_percentage": 15.524880708929789
  },
  "professional_network_followers_count_by_month": [
    {
      "follower_count": 3719,
      "date": "2022-08"
    },
    {
      "follower_count": 5868,
      "date": "2024-04"
    },
    {
      "follower_count": 1175,
      "date": "2020-04"
    },
    {
      "follower_count": 2853,
      "date": "2021-12"
    },
    {
      "follower_count": 4337,
      "date": "2023-01"
    },
    {
      "follower_count": 4187,
      "date": "2022-12"
    },
    {
      "follower_count": 2594,
      "date": "2021-10"
    },
    {
      "follower_count": 2653,
      "date": "2021-11"
    },
    {
      "follower_count": 4380,
      "date": "2023-02"
    },
    {
      "follower_count": 1409,
      "date": "2020-07"
    },
    {
      "follower_count": 3614,
      "date": "2022-07"
    },
    {
      "follower_count": 6476,
      "date": "2024-10"
    },
    {
      "follower_count": 5474,
      "date": "2024-01"
    },
    {
      "follower_count": 2482,
      "date": "2021-08"
    },
    {
      "follower_count": 1031,
      "date": "2020-01"
    },
    {
      "follower_count": 887,
      "date": "2019-09"
    },
    {
      "follower_count": 5028,
      "date": "2023-08"
    },
    {
      "follower_count": 5996,
      "date": "2024-05"
    },
    {
      "follower_count": 6683,
      "date": "2025-02"
    },
    {
      "follower_count": 6501,
      "date": "2024-11"
    },
    {
      "follower_count": 744,
      "date": "2019-05"
    },
    {
      "follower_count": 2070,
      "date": "2021-03"
    },
    {
      "follower_count": 959,
      "date": "2019-11"
    },
    {
      "follower_count": 4593,
      "date": "2023-04"
    },
    {
      "follower_count": 5081,
      "date": "2023-09"
    },
    {
      "follower_count": 1400,
      "date": "2020-06"
    },
    {
      "follower_count": 2186,
      "date": "2021-04"
    },
    {
      "follower_count": 2285,
      "date": "2021-05"
    },
    {
      "follower_count": 813,
      "date": "2019-06"
    },
    {
      "follower_count": 1624,
      "date": "2020-10"
    },
    {
      "follower_count": 6545,
      "date": "2024-12"
    },
    {
      "follower_count": 5337,
      "date": "2023-11"
    },
    {
      "follower_count": 4538,
      "date": "2023-03"
    },
    {
      "follower_count": 5574,
      "date": "2024-02"
    },
    {
      "follower_count": 2419,
      "date": "2021-07"
    },
    {
      "follower_count": 5168,
      "date": "2023-10"
    },
    {
      "follower_count": 664,
      "date": "2019-02"
    },
    {
      "follower_count": 3290,
      "date": "2022-05"
    },
    {
      "follower_count": 1827,
      "date": "2021-01"
    },
    {
      "follower_count": 4811,
      "date": "2023-06"
    },
    {
      "follower_count": 3502,
      "date": "2022-06"
    },
    {
      "follower_count": 2979,
      "date": "2022-02"
    },
    {
      "follower_count": 2941,
      "date": "2022-01"
    },
    {
      "follower_count": 6425,
      "date": "2024-09"
    },
    {
      "follower_count": 838,
      "date": "2019-07"
    },
    {
      "follower_count": 3204,
      "date": "2022-04"
    },
    {
      "follower_count": 6049,
      "date": "2024-06"
    },
    {
      "follower_count": 1787,
      "date": "2020-12"
    },
    {
      "follower_count": 2323,
      "date": "2021-06"
    },
    {
      "follower_count": 3110,
      "date": "2022-03"
    },
    {
      "follower_count": 4750,
      "date": "2023-05"
    },
    {
      "follower_count": 1315,
      "date": "2020-05"
    },
    {
      "follower_count": 1058,
      "date": "2020-02"
    },
    {
      "follower_count": 4932,
      "date": "2023-07"
    },
    {
      "follower_count": 1514,
      "date": "2020-08"
    },
    {
      "follower_count": 887,
      "date": "2019-08"
    },
    {
      "follower_count": 723,
      "date": "2019-03"
    },
    {
      "follower_count": 1706,
      "date": "2020-11"
    },
    {
      "follower_count": 6597,
      "date": "2025-01"
    },
    {
      "follower_count": 5732,
      "date": "2024-03"
    },
    {
      "follower_count": 3769,
      "date": "2022-09"
    },
    {
      "follower_count": 664,
      "date": "2019-01"
    },
    {
      "follower_count": 3884,
      "date": "2022-10"
    },
    {
      "follower_count": 6174,
      "date": "2024-07"
    },
    {
      "follower_count": 995,
      "date": "2019-12"
    },
    {
      "follower_count": 1922,
      "date": "2021-02"
    },
    {
      "follower_count": 6768,
      "date": "2025-03"
    },
    {
      "follower_count": 1118,
      "date": "2020-03"
    },
    {
      "follower_count": 3946,
      "date": "2022-11"
    },
    {
      "follower_count": 5394,
      "date": "2023-12"
    },
    {
      "follower_count": 6255,
      "date": "2024-08"
    },
    {
      "follower_count": 1591,
      "date": "2020-09"
    },
    {
      "follower_count": 887,
      "date": "2019-10"
    },
    {
      "follower_count": 2550,
      "date": "2021-09"
    },
    {
      "follower_count": 744,
      "date": "2019-04"
    },
    {
      "follower_count": 6779,
      "date": "2025-04"
    }
  ],
  "active_job_postings_count_change": null,
  "product_reviews_score_change": null,
  "product_reviews_score_by_month": [],
  "total_website_visits_change": null,
  "total_website_visits_by_month": [],
  "employee_reviews_score_aggregated_change": null,
  "employee_reviews_score_aggregated_by_month": [],
  "employee_reviews_score_business_outlook_change": null,
  "employee_reviews_score_business_outlook_by_month": [],
  "employee_reviews_score_career_opportunities_change": null,
  "employee_reviews_score_career_opportunities_by_month": [],
  "employee_reviews_score_ceo_approval_change": null,
  "employee_reviews_score_ceo_approval_by_month": [],
  "employee_reviews_score_compensation_benefits_change": null,
  "employee_reviews_score_compensation_benefits_by_month": [],
  "employee_reviews_score_culture_values_change": null,
  "employee_reviews_score_culture_values_by_month": [],
  "employee_reviews_score_diversity_inclusion_change": null,
  "employee_reviews_score_diversity_inclusion_by_month": [],
  "employee_reviews_score_recommend_change": null,
  "employee_reviews_score_recommend_by_month": [],
  "employee_reviews_score_senior_management_change": null,
  "employee_reviews_score_senior_management_by_month": [],
  "employee_reviews_score_work_life_balance_change": null,
  "employee_reviews_score_work_life_balance_by_month": [],
  "expired_domain": 0,
  "unique_domain": 1,
  "unique_website": 1,
  "last_updated_at": "2025-04-04",
  "created_at": "2016-06-25",
  "industry_group_1": "Biotech",
  "industry_group_2": null
}

Deep-dive with exact details about Biotech companies in Botswana

Your data must have high quality if you want to turn it into valuable insights. Arm yourself with the latest intel that will paint the big picture about emerging Biotech industry trends and tell you granular, company-level stories.

Each Botswana Biotech company profile, collected and enriched by Coresignal, includes:

  • Main company information. Data about the industry, company’s size, technology stack, and contact information.
  • Biotech workforce trends. Insights into the organization’s leadership and a timeline of job changes within the company or industry.
  • Financials and funding. Information about the company’s revenue, funding history, and ownership.
  • Growth insights. Changes in employee count, number of social media followers, and competitor activity.
  • Online presence overview. Growth in the company’s website traffic, social media activity, customer reviews, and media coverage.
  • Product information. Summary of product pricing and customer reviews.

Combined, these data points create the most comprehensive Biotech companies in Botswana database. With 500+ data points for analysis, you can be sure to find the answer to any question about the industry.

Easy solution to cover all company data needs at scale

API Logo

Access data as comprehensive dataset files or via an API

Data enrichment logo

Boost your existing dataset with the no-code data enrichment tool

Company logo

Find competitors and similar companies

Talent analytics logo

Track headcount changes

Historical data logo

Review Botswana historical company data

Collect credits logo

200 free collect and 400 search credits

Buy a list of Biotech companies in Botswana

Unlock the Botswana Biotech sector with Coresignal's extensive datasets and data APIs

With over 11 company profiles, you can easily access detailed information to analyze the market, conduct competitive analysis, and qualify sales leads.

You can purchase our data directly through our self-service platform, or integrate it seamlessly into your systems via data APIs. Whether you need a one-time dataset or continuous access, Coresignal offers flexible solutions to meet your needs.

Globe
Country hero image

What is Coresignal?

Coresignal is a public web data vendor that delivers fresh data about companies, professionals, and jobs for 500+ leading companies in market research, venture capital investment, HR tech, sales, and marketing industries. Founded in 2016, the company is known for its high-quality, fresh data and professional service. Coresignal is a member of the Ethical Web Data Collection Initiative and supports academic institutions with data for research.

9 years

in the market

500+

clients

3B+

data records

Frequently asked questions

Why source Botswana Biotech companies database from Coresignal?

Coresignal provides fresh, high-quality web data about millions of companies in 190+ countries. You can easily find data about Botswana Biotech companies, filter it to fit your needs better, download the information as a dataset, or access it via a data API.

How to get a list of Biotech companies in Botswana?

Once you log in to the self-service platform, choose the type of companies you want to review by picking the "Company" and "Country" filters. Review the data sample returned and download up to 200 company profiles for free to check how well the data fits your goal.

If you have an even more specific question in mind, such as how I can find all companies of a specific category residing within my state, you can easily add more filters to the query. The more specific the request, the better your results will be.

How to track Biotech company changes in Botswana?

Get notifications about changes in employee headcount, funding, revenue, and other features by setting up Coresignal's webhooks. Webhooks are automated messages that notify you about data changes in a company of interest, such as a potential client or a competitor.

What details are included in the profiles of Botswana Biotech companies?

Company profiles contain more than 500 different data points. Generally, the data is sorted into six categories: company overview, workforce trends, growth insights, product summary, online presence, and financial information.

If you have specific details, please review the information listed above, visit Coresignal's , or .

Can I access historical data on Biotech companies in Botswana?

You can access years of historical data on Biotech companies in Botswana, which enables you to use this information for competitive analysis or market research. Find out if your target companies were growing, how well they were doing financially, and if there were any significant changes in their leadership. By diving deep into the historical data, get to know the Botswana Biotech market better.

How can I request a sample or demo of your data on Botswana Biotech companies?

Definitely! Coresignal's self-service allows you to get 200 data records free of charge. All you have to do is register for an account and explore its possibilities.

If you are unsure how to achieve your preferred results, you can always and get some help from our data experts.